Botox 100 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FKKK2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,396
Award facts
- Contract value 100% obligated
- $14,396.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
On January 7, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $14,396.10 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of BOTOX 100 Unit Vials. This firm fixed-price delivery order, which is not set-aside designated, is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The IDC, awarded on November 13, 2025, carries a $499.999 billion ceiling value and runs through December 31, 2036, positioning the contractor as a critical pharmaceutical supplier for Department of Defense healthcare operations worldwide. Performance is scheduled for completion by January 29, 2026, at the contractor's facility in Park Ridge, Illinois.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity and competitive capability through numerous delivery orders issued by the DLA's Medical Supply Chain division, supplying an extensive portfolio of pharmaceuticals including branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals to support military healthcare facilities. The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors capable of fulfilling the diverse and specialized pharmaceutical requirements of the federal military medical system on a recurring basis.
Quick answers
Who was awarded contract SPE2DR26FKKK2?
SPE2DR26FKKK2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26FKKK2 worth?
The government has obligated $14,396 on SPE2DR26FKKK2.
Is contract SPE2DR26FKKK2 an order under another contract?
Yes. SPE2DR26FKKK2 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKK2 competed?
The extent of competition for SPE2DR26FKKK2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award